SEQUENT

Jan 22 (Reuters) - SeQuent Scientific Ltd SEQU.NS:

• CCI APPROVES SEQUENT SCIENTIFIC'S AMALGAMATION SCHEME

Source text: ID:nBSE96y2PS

Further company coverage: SEQU.NS

(([email protected];;))

Nov 13 (Reuters) - SeQuent Scientific Ltd SEQU.NS:

• SEQUENT SCIENTIFIC SEPT-QUARTER CONSOL NET PROFIT 26.1 MILLION RUPEES

• SEQUENT SCIENTIFIC SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 3.69 BILLION RUPEES

Source text: [ID:]

Further company coverage: SEQU.NS

(([email protected];))

** Shares of SeQuent Scientific SEQU.NS jump 13.5% to hit its highest since Oct. 2021

** The animal healthcare firm announced merger with pharma co, Viyash Lifesciences

** Merger will accelerate R&D operations and aid new product development, increase customer presence - SEQU

** Post merger, shareholders of Viyash will be issued 56 shares of SeQuent for every 100 shares held in Viyash

** Stock eyes busiest trading session since Oct. 2023, volumes at 8.5x the 30-day avg

** SEQU up 25.4% so far this week, its biggest weekly gain since Nov. 2023

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

** Shares of SeQuent Scientific SEQU.NS rise as much as 11.1% to 175 rupees, highest since Jan 21, 2022

** Stock eyes fourth straight session of gains

** The pharma co said on Monday it got pre-qualification approval from World Health Organization (WHO) for Albendazole, API

** Albendazole medication is used to treat parasitic infections including tapeworm and roundworm

** More than 4.3 mln shares change hands, 2x its 30-day avg

** Stock up 39% so far this year; eyes best yearly gain since 2020

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

Aug 19 (Reuters) - SeQuent Scientific Ltd SEQU.NS:

• GETS WHO PREQUALIFICATION APPROVAL FOR ALBENDAZOLE API

Source text for Eikon: ID:nBSE7BNkxd

Further company coverage: SEQU.NS

(Reporting by VijayDattaram Malkar)

(([email protected];))

Aug 14 (Reuters) - SeQuent Scientific Ltd SEQU.NS:

• SEQUENT SCIENTIFIC JUNE-QUARTER CONSOL NET PROFIT 65.1 MILLION RUPEES

• SEQUENT SCIENTIFIC JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 3.9 BILLION RUPEES

Further company coverage: SEQU.NS

(([email protected];))

Feb 5 (Reuters) - SeQuent Scientific Ltd SEQU.NS:

• APPROVED DIVESTMENT OF ITS SHAREHOLDING AND BENEFICIAL INTEREST IN UNIT

Source text for Eikon: ID:nBSE19ZJx7

Further company coverage: SEQU.NS

(([email protected];))

** Shares of SeQuent Scientific SEQU.NS climb as much as 9.5% to 96.15 rupees; logging their best pct gain since June 22

** The animal healthcare co says it approved a sale of its drug ingredient facility in Thane, Maharashtra; deal value not disclosed

** Stock hits highest since Aug. 31

** Nearly 7.5 mln shares change hands, 4.2x the 30-day average of ~1.8 mln shares

** Stock remains flat this year, as of last close

(Reporting by Archishma Iyer in Bengaluru)

(([email protected];))

Aug 9 (Reuters) - SeQuent Scientific Ltd SEQU.NS:

• SEQUENT SCIENTIFIC LTD - SPAIN UNIT MERGES WITH UNIT VILA VIÑA PARTICIPACION, S.L., SPAIN

Source text for Eikon: ID:nBSE6c6X6R

Further company coverage: SEQU.NS

(([email protected];))

July 14 (Reuters) - SeQuent Scientific Ltd SEQU.NS:

• DISCONTINUED ITS MANUFACTURING OPERATIONS AT ITS UNIT IN TARAPUR

Source text for Eikon: ID:nBSE209dbK

Further company coverage: SEQU.NS

(([email protected];))

** Shares of Sequent Scientific Ltd SEQU.NS fall as much as 8.67% to an one-month low of 70.60 rupees

** Co reports consolidated net loss of 935.75 mln rupees in March quarter compared to a profit of 88.26 mln rupees a year ago

** Results of the quarter reflect a one-time change on closure of manufacturing in Germany and fall in demand in Turkey due to the devastating earthquake during the March quarter: Co

** Pricing pressures and currency challenges in some markets also dragged demand and earnings, co says

** Trading volume is 3.37 mln shares as of 12:17 p.m. IST, 1.6x the 30-day avg - Refinitiv data

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))